Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Management of ulcerative colitis in a real-life setting: An Italian multicenter, prospective, observational AIGO study.
Scribano ML, Papi C, Costa F, Bortoli A, Bortoluzzi F, Buscarini E, Cappello M, Caserta L, Cortelezzi C, Ferronato A, Manguso F, Mazzuoli S, Orzes N, Kohn A; AIGO IBD Study Group. Scribano ML, et al. Among authors: ferronato a. Dig Liver Dis. 2019 Mar;51(3):346-351. doi: 10.1016/j.dld.2018.08.006. Epub 2018 Aug 16. Dig Liver Dis. 2019. PMID: 30195815
Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study.
Pugliese D, Privitera G, Rogai F, Variola A, Viola A, Laterza L, Privitera AC, Allocca M, Bossa F, Cappello M, Daperno M, Lorenzon G, Mazzuoli S, Principi M, Sablich R, Moser L, Ferronato A, Traini S, Tapete G, Bodini G, Di Girolamo M, Grossi L, Mocci G, Ricci C, Saibeni S, Festa S, Spagnuolo R, Cortelezzi CC, Mocciaro F, Rizzello F, Armuzzi A; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Pugliese D, et al. Among authors: ferronato a. United European Gastroenterol J. 2021 Feb;9(1):102-109. doi: 10.1177/2050640620974308. Epub 2021 Mar 1. United European Gastroenterol J. 2021. PMID: 33203342 Free PMC article.
Switching from Infliximab Originator to SB2 Biosimilar in Inflammatory Bowel Diseases: A Multicentric Prospective Real-Life Study.
Massimi D, Barberio B, Bertani L, Costa F, Ferronato A, Facchin S, Cardin R, Cingolani L, Casadei C, D'Incà R, Zingone F, Savarino EV. Massimi D, et al. Among authors: ferronato a. Therap Adv Gastroenterol. 2021 Jun 27;14:17562848211023384. doi: 10.1177/17562848211023384. eCollection 2021. Therap Adv Gastroenterol. 2021. PMID: 34249147 Free PMC article.
A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study.
Barberio B, Cingolani L, Canova C, Barbieri G, Sablich R, Urbano MT, Bertani L, Costa F, Bodini G, Demarzo MG, Ferronato A, Buda A, Melatti P, Massimi D, Savarino EV, Zingone F. Barberio B, et al. Among authors: ferronato a. Therap Adv Gastroenterol. 2021 Jul 20;14:17562848211031420. doi: 10.1177/17562848211031420. eCollection 2021. Therap Adv Gastroenterol. 2021. PMID: 34349836 Free PMC article.
Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study.
Bezzio C, Armuzzi A, Furfaro F, Ardizzone S, Milla M, Carparelli S, Orlando A, Caprioli FA, Castiglione F, Viganò C, Ribaldone DG, Zingone F, Monterubbianesi R, Imperatore N, Festa S, Daperno M, Scucchi L, Ferronato A, Pastorelli L, Balestrieri P, Ricci C, Cappello M, Felice C, Fiorino G, Saibeni S; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Bezzio C, et al. Among authors: ferronato a. Aliment Pharmacol Ther. 2021 Dec;54(11-12):1432-1441. doi: 10.1111/apt.16663. Epub 2021 Oct 25. Aliment Pharmacol Ther. 2021. PMID: 34694009 Free PMC article.
Long-term, Real-life, Observational Study in Treating Outpatient Ulcerative Colitis with Golimumab.
Tursi A, Mocci G, Elisei W, Allegretta L, Colucci R, Della Valle N, De Medici A, Faggiani R, Ferronato A, Forti G, Larussa T, Lorenzetti R, Luzza F, Penna A, Pranzo G, Rodinò S, Sacco R, Sebkova L, Zampaletta C, Graziosi C, Picchio M, Bergna IMB, Maconi G. Tursi A, et al. Among authors: ferronato a. J Gastrointestin Liver Dis. 2021 Dec 21;30(4):456-461. doi: 10.15403/jgld-3992. J Gastrointestin Liver Dis. 2021. PMID: 34812437 Free article.
I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease.
Peyrin-Biroulet L, Rahier JF, Kirchgesner J, Abitbol V, Shaji S, Armuzzi A, Karmiris K, Gisbert JP, Bossuyt P, Helwig U, Burisch J, Yanai H, Doherty GA, Magro F, Molnar T, Löwenberg M, Halfvarson J, Zagorowicz E, Rousseau H, Baumann C, Baert F, Beaugerie L; I-CARE Collaborator Group. Peyrin-Biroulet L, et al. Clin Gastroenterol Hepatol. 2023 Mar;21(3):771-788.e10. doi: 10.1016/j.cgh.2022.09.018. Epub 2022 Sep 22. Clin Gastroenterol Hepatol. 2023. PMID: 36152897 Free article.
Use of tofacitinib as first or second-line therapy is associated with better outcomes in patients with ulcerative colitis: data from a real-world study.
Tursi A, Mocci G, Cingolani L, Savarino E, Pica R, Cocco A, Zippi M, Napolitano D, Schiavoni E, Pugliese D, Scaldaferri F, Costa F, Marzo M, Serio M, Scarcelli A, Bolognini L, Bendia E, Maconi G, Cannatelli R, Piergallini S, Bodini G, Calabrese F, Ferronato A, Pranzo G, Elisei W, Monterubbianesi R, Faggiani R, Rodinò S, Sebkova L, Grossi L, Gaiani F, Dè Angelis G, Lorenzetti R, Allegretta L, Cazzato AI, Scorza S, Della Valle N, Sacco R, Forti G, Colucci R, Tonti P, Neve V, Rocco G, Sacchi C, Zampaletta C, Pagnini C, Graziani MG, Di Paolo MC, Onidi FM, Usai Satta P, Picchio M, Papa A. Tursi A, et al. Among authors: ferronato a. Expert Opin Pharmacother. 2023 Sep-Dec;24(14):1649-1656. doi: 10.1080/14656566.2023.2230126. Epub 2023 Jun 28. Expert Opin Pharmacother. 2023. PMID: 37358928
61 results